郑一超
教授，硕士生导师/博士生导师，河南省药品质量控制与评价重点实验室副主任、河南省化学药物工程研究中心副主任
邮箱：yichaozheng@hotmail.com
研究方向：表观遗传靶向药物发现及其药理活性研究
个人简介
本、硕、博士先后毕业于中国药科大学、比利时鲁汶大学和郑州大学。现为郑州大学药学院教授、博士生/博士后导师、省部共建食管癌防治国家重点实验室和药物关键制备技术教育部重点实验室骨干成员。担任河南省药品质量控制与评价重点实验室副主任、河南省化学药物工程研究中心副主任、中国病理生理学会蛋白质修饰与疾病专业委员会委员、中国药理学会化疗专业委员会青年副主委、河南省医养结合研究会副会长、河南省药学会药物化学专业委员会委员，入选河南省青年拔尖人才、河南省青年托举人才、郑州市创新紧缺人才、郑州市第九届青年科学奖，河南省优秀博士论文。担任International Immunopharmacology(IF=5.6分)副主编Drug Resistance Updates (IF=22.8分)编委、Aging Dis.和Acupunct. Herb. Med.青年编委。主持科技部重点研发计划子课题、国家自然科学基金、河南省重点研发计划等省部级科研项目13项。
主要从事表观遗传靶向药物发现及其药理活性研究。先后以第一作者/通讯作者发表高水平论文88篇，包括J. Med. Chem.、Mol. Cancer、J. Hematol. Oncol.、Acta. Pharm. Sin. B.、EMBO Rep.、Med. Res. Rev.等高水平论文，最高影响因子41.44分，H-index为32，近五年所发表文章被引用超过3600次，其中封面文章2篇，ESI前1%高被引4篇。所发现多个化合物已被MCE等公司作为阳性化合物出售，授权专利15项，多篇文章被科学网、Nature Reviews in Drug Discovery、中国科学报、iNature作为亮点报道。培养校级优秀毕业论文获得者4人，河南省优秀毕业论文获得者2人。
教学与教研
主要教授高等药物化学等硕士研究生及本科生课程。培养校级优秀毕业论文获得者4人，河南省优秀毕业论文获得者2人。部分省部级以上教学与教研奖励及成果如下：
1)2016年河南省卫生和计划生育委员会医学教育科学研究和推广突出贡献
2)2020年河南省教育厅，物质结构测定虚拟仿真系统，二等奖
3)2021年河南省教育厅，河南省优秀硕士学位论文指导老师
4)2021年河南省教育厅，河南省研究生教育改革与质量提升工程项目
5)2022年河南省教育厅，河南省优秀硕士学位论文指导老师
科研项目
主持科技部重点研发计划子课题、国家自然科学基金、河南省重点研发计划等科研项目13项。先后成功开发国内第一个《组蛋白提取试剂盒》及《超灵敏CCK8细胞增殖检测试剂盒》，所设计、合成多个化合物已被MCE等公司作为阳性化合物出售。部分科研项目如下所列：
1)河南省重点研发专项（2024）
2)河南省青年拔尖人才（2023年）
3)河南省高等学校重点科研项目计划基础研究专项（2021年）
4)河南省科技厅基础与前沿技术研究（2020）
5)河南省青年托举人才（2020年）
6)科技部国家重点研发计划政府间国际科技创新合作重点专项（2019）
7)郑州市创新紧缺人才（2019年）
8)国家自然科学基金（2017）
9)河南省科技厅基础与前沿技术研究（2016）
10)河南省教育厅高等学校重点科研项目（2015）
研究与成果
主要从事表观遗传靶向药物发现及其药理活性研究。先后以第一作者/通讯作者发表高水平论文88篇，包括Mol. Cancer、J. Hematol. Oncol.、Acta. Pharm. Sin. B.、J. Med. Chem.、EMBO Rep.、Pharmacol. Ther.、Int. J. Biol. Macromol.、Med. Res. Rev.等高水平论文，最高影响因子41.44分，H-index为32，近五年所发表文章被引用超过3600次，其中封面文章2篇，ESI前1%高被引4篇。授权专利16项，其中一项专利被Nature Reviews in Drug Discovery以新闻形式报道，为该期报道中唯一一个中国专利。
实验室发表文章清单（实时更新）：https://www.yichaozheng.cn/publications/或https://orcid.org/0000-0002-2662-3770或http://scholar.google.com/citations?user=0dpxap0AAAAJ&hl=en。
部分代表性文章如下：
1)Hui-Min Liu, Ying Zhou, He-Xiang Chen, Jiang-Wan Wu, Shi-Kun Ji, Liang Shen, Shao-Peng Wang, Hong-Min Liu, Ying Liu*, Xing-Jie Dai*, Yi-Chao Zheng*. LSD1 in drug discovery: From biological function to clinical application. Medicinal Research Reviews, 2024, 44(2):833-866.
2)Binglei Zhang, Jianxiang Shi, Xiaojing Shi, Xiaolu Xu, Le Gao, Song Li, Mengmeng Liu, Mengya Gao, Shuiling Jin, Jian Zhou, Dandan Fan, Fang Wang, Zhenyu Ji, Zhilei Bian, Yongping Song, Wenzhi Tian, Yichao Zheng*, Linping Xu*, Wei Li*. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Drug Resistance Updates, 2024, 74, 101068.
3)Yan-Jia Guo, Jing-Ru Pang, Yu Zhang, Zhong-Rui Li, Xiao-Lin Zi, Hong-Min Liu, Ning Wang, Li-Juan Zhao, Ya Gao, Bo Wang, Piet Herdewijn, Cheng-Yun Jin*, Ying Liu*, Yi-Chao Zheng*. Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer. International Journal of Biological Macromolecules, 2024, 254(3), 126801.
4)Xing-Jie Dai, Ying Liu, Ning Wang, He-Xiang Chen, Jiang-Wan Wu, Xiao-Peng Xiong, Shi-Kun Ji, Ying Zhou, Liang Shen, Shao-Peng Wang, Hong-Min Liu, Hui-Min Liu*, Yi-Chao Zheng*. Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer. European Journal of Medicinal Chemistry, 2023, 259, 115684.
5)Hui-Min Liu, Xiao-Peng Xiong, Jiang-Wan Wu, He-Xiang Chen, Ying Zhou, Shi-Kun Ji, Xing-Jie Dai*, Yi-Chao Zheng*, Hong-Min Liu*. Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer. European Journal of Medicinal Chemistry, 2023, 251, 115255.
6)Xing-Jie Dai, Li-Juan Zhao, Long-Hua Yang, Ting Guo, Lei-Peng Xue, Hong-Mei Ren, Zhi-Li Yin, Xiao-Peng Xiong, Ying Zhou, Shi-Kun Ji, Hui-Min Liu, Hong-Min Liu*, Ying Liu*, and Yi-Chao Zheng*. Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells. Journal of Medicinal Chemistry, 2023, 66(6):3896–3916.
7)Dan-Dan Shen, Jing-Ru Pang, Ya-Ping Bi, Long-Fei Zhao, Yin-Rui Li, Li-Juan Zhao, Ning Wang, Ya Gao, Bo Wang, Hong-Min Liu*, Yi-Chao Zheng*. LSD1 deletion decreases exsomal PD-L1 and restores T cell response in gastric cancer. Molecular Cancer, 2022, 21: 75.
8)Long-Fei Zhao, Jin-Ge Zhang, Feng-Yu Qi, Wei-Yan Hou, Yin-Rui Li, Dan-Dan Shen, Li-Juan Zhao, Lin Qi*, Hong-Min Liu*, Yi-Chao Zheng*. SDC: An Integrated Database for Sex Differences in Cancer. Computational and Structural Biotechnology Journal, 2022, 20, 1068-1076.
9)Li-Juan Zhao, Ying-Ying Li, Yu-Tong Zhang, Qi-Qi Fan, Hong-Mei Ren, Cheng Zhang, Adil Mardinoglu, Wen-Chao Chen, Jing-Ru Pang, Dan-Dan Shen, Jun-Wei Wang, Long- Fei Zhao, Jian-Ying Zhang, Zhen-Ya Wang, Yi-Chao Zheng* and Hong-Min Liu*. Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness. Embo Reports, 2021, e50922.
10)Yi-Chao Zheng, Yan-Jia Guo, Bo Wang, Chong Wang, M.A.A. Mamun, Ya Gao*, Hong-Min Liu*. Targeting neddylation E2s: a novel therapeutic strategy in cancer. Journal of Hematology & Oncology, 2021, 14:57.
11)Xing-Jie Dai, Ying Liu, Lei-Peng Xue, Xiao-Peng Xiong, Ying Zhou, Yi-Chao Zheng*, and Hong-Min Liu*. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1. Journal of Medicinal Chemistry, 2021, 64, 5, 2466–2488.
12)Zhiru Wang, Wenting Kang, Ouwen Li, Fengyu Qi, Junwei Wang, Yinghua You, Pengxing He, Zhenhe Suo, Yichao Zheng*, Hongmin Liu*. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharmaceutica Sinica B, 2021, 11 (3), 694-707.
13)Li-Juan Zhao, Qi-Qi Fan, Ying-Ying Li, Hong-Mei Ren, Ting Zhang, Shuan Liu, Mamun Maa, Yi-Chao Zheng*, Hong-MinLiu*. LSD1 deletion represses gastric cancer migration by upregulating a novel miR-142-5p target protein CD9. Pharmacological Research, 2020, 159, 104991.
14)Liying Ma, Haojie Wang, Yinghua You, Chaoya Ma, Yuejiao Liu, Feifei Yang, Yichao Zheng*, Hongmin Liu*. Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors. Acta Pharmaceutica Sinica B, 2020, 10(6): 1658-1668.
15)Hong-Min Liu, Feng-Zhi Suo, Xiao-Bo Li, Ying-Hua You, Chun-Tao Lv, Chen-Xing Zheng, Guo-Chen Zhang, Yue-Jiao Liu, Wen-Ting Kang, Yi-Chao Zheng*, Hai-Wei Xu*. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors. European Journal of Medicinal Chemistry, 2019, 175, 357-372.
16)Shuai Wang, Lijie Zhao, Xiao-Jing Shi, Lina Ding, Linlin Yang, Zhi-Zheng Wang, Dandan Shen, Kai Tang, Xiao-Jing Li, MAA Mamun, Huiju Li, Bin Yu*, Yi-Chao Zheng*, Shaomeng Wang*, and Hong-Min Liu*. Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 5, 2772-2797.
17)Zhonghua Li, Lina Ding, Zhongrui Li, Zhizheng Wang, Fengzhi Suo, Dandan Shen, Taoqian Zhao, Xudong Sun, Junwei Wang, Ying Liu, Liying Ma, Bing Zhao, Pengfei Geng, Bin Yu*, Yichao Zheng*, Hongmin Liu*. Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A). Acta Pharmaceutica Sinica B. 2019, 9(4): 794-808.
18)Yi-Chao Zheng, Jinlian Ma, Zhiru Wang, Jinfeng Li, Bailing Jiang, Wenjuan Zhou, Xiaojing Shi, Xixin Wang, Wen Zhao and Hong-Min Liu*. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors. Medicinal Research Reviews, 2015, 35, 1032-1071.
19)Li-Ying Ma#, Yi-Chao Zheng#, Sai-Qi Wang#, Bo Wang, Zhi-Ru Wang, Lu-Ping Pang, Miao-Zhang, Jun-Wei Wang, Li-Na Ding, Juan Li, Cong Wang, Biao Hu, Ying Liu, Xiao-Dan Zhang, Jia-Jia Wang, Zhi-Jian Wang, Wen Zhao* and Hong-Ming Liu*. Design, synthesis and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea-hybrids as potent, orally active antitumor agents. Journal of Medicinal Chemistry, 2015, 58, 1705-1716.
20)Yi-Chao Zheng#, Ying-Chao Duan#, Jin-Lian Ma, Rui-Min Xu, Xiaolin Zi, Wen-Lei Lv, Meng-Meng Wang, Xian-Wei Ye, Shun Zhu, David Mobley, Yan-Yan Zhu, Jun-Wei Wang, Jin-Feng Li, Zhi-Ru Wang, Wen Zhao, Hong-Min Liu*. Triazole-dithiocarbamate based, selective LSD1 inactivators inhibit gastric cancer cell growth, invasion and migration, Journal of Medicinal Chemistry, 2013, 56, 8543-8560.
实验室概况
实验室依托省部共建食管癌防治国家重点实验室、药物关键制备技术教育部重点实验、河南省药品质量控制与评价重点实验室和河南省化学药物工程研究中心，具备完善的药物设计、合成及药理学研究平台。诚邀药物化学、药物设计、药理学、生物化学、分子生物学、基础医学等方向青年教师、博士后、硕士博士研究生加入！
实验室网址（实时更新）：https://www.yichaozheng.cn/
